Vitamin D insufficiency and prognosis in chronic lymphocytic leukemia

Blood

Volumn 117, Issue 5, 2011, Pages 1492-1498

  Shanafelt, Tait D ^a   Drake, Matthew T ^a   Maurer, Matthew J ^a   Allmer, Cristine ^a   Rabe, Kari G ^a   Slager, Susan L ^a   Weiner, George J ^b   Call, Timothy G ^a   Link, Brian K ^b   Zent, Clive S ^a   Kay, Neil E ^a   Hanson, Curtis A ^a   Witzig, Thomas E ^a   Cerhan, James R ^a  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALPHA4 INTEGRIN; CD38 ANTIGEN; IMMUNOGLOBULIN HEAVY CHAIN; PROTEIN KINASE ZAP 70;

ADULT; ARTICLE; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENDER; GENE MUTATION; HUMAN; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; VITAMIN BLOOD LEVEL; VITAMIN D DEFICIENCY;

EID: 79551638238     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-295683     Document Type: Article

References (45)

1. Thomas MK, Lloyd-Jones DM, Thadhani RI, et al. Hypovitaminosis D in medical inpatients. N Engl J Med. 1998;338(12):777-783.
2. Holick MF. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc. 2006;81(3):353-373. (Pubitemid 43334631)
3. Holick MF. Vitamin D deficiency. N Engl J Med. 2007;357(3):266-281.
4. Carlberg C. Current understanding of the function of the nuclear vitamin D receptor in response to its natural and synthetic ligands. Recent Results Cancer Res. 2003;164:29-42.
5. Bikle D. Nonclassic actions of vitamin D. J Clin Endocrinol Metab. 2009;94(1):26-34.
6. Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol. 2005;97(1-2):179-194.
7. Yin L, Grandi N, Raum E, Haug U, Arndt V, Brenner H. Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Aliment Pharmacol Ther. 2009;30(2):113-125.
8. Crew KD, Shane E, Cremers S, McMahon DJ, Irani D, Hershman DL. High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol. 2009;27(13):2151-2156.
9. Chen P, Hu P, Xie D, Qin Y, Wang F, Wang H. Meta-analysis of vitamin D, calcium and the prevention of breast cancer. Breast Cancer Res Treat. 2010;121(2):469-477.
10. Garland CF, Gorham ED, Mohr SB, Garland FC. Vitamin D for cancer prevention: global perspective. Ann Epidemiol. 2009;19(7):468-483.
11. Lappe JM, Travers-Gustafson D, Davies KM, Recker RR, Heaney RP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586-1591.
12. Ng K, Meyerhardt JA, Wu K, et al. Circulating 25-hydroxyvitamin d levels and survival in patients with colorectal cancer. J Clin Oncol. 2008;26(18):2984-2991.
13. Goodwin PJ, Ennis M, Pritchard KI, Koo J, Hood N. Prognostic effects of 25-hydroxyvitamin D levels in early breast cancer. J Clin Oncol. 2009;27(23):3757-3763.
14. Newton-Bishop JA, Beswick S, Randerson-Moor J, et al. Serum 25-hydroxyvitamin D3 levels are associated with breslow thickness at presentation and survival from melanoma. J Clin Oncol. 2009;27(32):5439-5444.
15. Zhou W, Heist RS, Liu G, et al. Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007;25(5):479-485.
16. Kricker A, Armstrong BK, Hughes AM, et al. Personal sun exposure and risk of non Hodgkin lymphoma: a pooled analysis from the Interlymph Consortium. Int J Cancer. 2008;122(1):144-154.
17. Giovannucci E, Liu Y, Rimm EB, et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451-459.
18. Lim U, Freedman DM, Hollis BW, et al. A prospective investigation of serum 25-hydroxyvitamin D and risk of lymphoid cancers. Int J Cancer. 2009;124(4):979-986.
19. Purdue MP, Freedman DM, Gapstur SM, et al. Circulating 25-hydroxyvitamin D and risk of non-hodgkin lymphoma: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol. 1010;172(1):58-69.
20. Weiner G, Witzig TE, Link BK. The University of Iowa/Mayo Clinic Lymphoma SPORE: SPORE update. Clin Adv Hematol Oncol. 2004;2:57-59.
21. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996;87(12):4990-4997. (Pubitemid 26189840)
22. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17(12):3835-3849.
23. Shanafelt TD, Witzig TE, Fink SR, et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated earlystage chronic lymphocytic leukemia. J Clin Oncol. 2006;24(28):4634-4641.
24. Shanafelt TD, Geyer SM, Bone ND, et al. CD49d expression is an independent predictor of overall survival in patients with chronic lymphocytic leukaemia: a prognostic parameter with therapeutic potential. Br J Haematol. 2008;140(5):537-546.
25. Shanafelt TD, Hanson C, Dewald GW, et al. Karyotype evolution on fluorescent in situ hybridization analysis is associated with short survival in patients with chronic lymphocytic leukemia and is related to CD49d expression. J Clin Oncol. 2008;26(14):e5-e6.
26. Dewald G, Brockman S, Paternoster S, et al. Chromosome anomalies detected by interphase fluorescence in hybridization: correlation with significant biological features of chronic lymphocytic leukemia. Br J Haematol. 2003;121(2):287-295.
27. Jelinek DF, Tschumper RC, Geyer SM, et al. Analysis of clonal B-cell CD38 and immunoglobulin variable region sequence status in relation to clinical outcome for B-chronic lymphocytic leukaemia. Br J Haematol. 2001;115(4):854-861.
28. Binkley N, Krueger D, Gemar D, Drezner MK. Correlation among 25-hydroxy-vitamin D assays. J Clin Endocrinol Metab. 2008;93(5):1804-1808.
29. Kaplan E, Meier P. Nonparametric estimation for incomplete observations. J Am Stat Assoc. 1958;53:457-481.
30. Cox DR. Regression models and life tables (with discussion). J R Stat Soc Series B Stat Methodol. 1972;34(2):187-220.
31. Eilers P, Marx B. Flexible smoothing with B-splines and penalties. Stat Sci. 1996;11(2):89-121.
32. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med. 2000;343(26):1910-1916. (Pubitemid 32064784)
33. Pepper C, ThomasA, Hoy T, Milligan D, Bentley P, Fegan C. The vitamin D3 analog EB1089 induces apoptosis via a p53-independent mechanism involving p38 MAP kinase activation and suppression of ERK activity in B-cell chronic lymphocytic leukemia cells in vitro. Blood. 2003;101(7):2454-2460.
34. Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer: potential for anticancer therapeutics. Nat Rev Cancer. 2007;7(9):684-700.
35. Provvedini DM, Tsoukas CD, Deftos LJ, Manolagas SC. 1,25-dihydroxyvitamin D3 receptors in human leukocytes. Science. 1983;221(4616):1181-1183.
36. Hickish T, Cunningham D, Colston K, et al. The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma. Br J Cancer. 1993;68(4):668-672.
37. Petrini M, Carulli G, Ambrogi F, Galbraith RM. Phenotypic markers in chronic lymphocytic leukemia. N Engl J Med. 1986;314(23):1514-1515. (Pubitemid 16114675)
38. Petrini M, Emerson DL, Galbraith RM. Linkage between surface immunoglobulin and cytoskeleton of B lymphocytes may involve Gc protein. Nature. 1983;306(5938):73-74.
39. Petrini M, Galbraith RM, Werner PA, Emerson DL, Arnaud P. Gc (vitamin D binding protein) binds to cytoplasm of all human lymphocytes and is expressed on B-cell membranes. Clin Immunol Immunopathol. 1984;31(2):282-295.
40. Constans J, Oksman F, Viau M. Binding of the apo and holo forms of the serum vitamin D-binding protein to human lymphocyte cytoplasm and membrane by indirect immunofluorescence. Immunol Lett. 1981;3(3):159-162.
41. Greenwald P, Anderson D, Nelson SA, Taylor PR. Clinical trials of vitamin and mineral supplements for cancer prevention. Am J Clin Nutr. 2007;85(1):314S-317S.
42. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. N Engl J Med. 1994;330(15):1029-1035.
43. Omenn GS, Goodman G, Thornquist M, et al. The beta-carotene and retinol efficacy trial (CARET) for chemoprevention of lung cancer in high risk populations: smokers and asbestos-exposed workers. Cancer Res. 1994;54(7 suppl):2038s-2043s.
44. Raina V, Cunningham D, Gilchrist N, Soukop M. Alfacalcidol is a nontoxic, effective treatment of follicular small-cleaved cell lymphoma. Br J Cancer. 1991;63(3):463-465.
45. Heaney RP. The Vitamin D requirement in health and disease. J Steroid Biochem Mol Biol. 2005;97(1-2):13-19.